475,551 Shares in INmune Bio, Inc. (NASDAQ:INMB) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new position in shares of INmune Bio, Inc. (NASDAQ:INMB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 475,551 shares of the company's stock, valued at approximately $2,221,000. Raymond James Financial Inc. owned about 2.15% of INmune Bio at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INMB. Wells Fargo & Company MN raised its stake in shares of INmune Bio by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock valued at $30,000 after buying an additional 2,155 shares during the last quarter. JPMorgan Chase & Co. raised its position in INmune Bio by 93.0% during the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock valued at $53,000 after acquiring an additional 5,461 shares in the last quarter. Jane Street Group LLC acquired a new position in INmune Bio in the third quarter valued at approximately $79,000. Financial Advocates Investment Management boosted its position in INmune Bio by 14.8% in the 4th quarter. Financial Advocates Investment Management now owns 15,500 shares of the company's stock worth $72,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of INmune Bio by 16.9% during the 4th quarter. Rhumbline Advisers now owns 16,744 shares of the company's stock worth $78,000 after purchasing an additional 2,424 shares during the period. 12.72% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

INMB has been the topic of a number of recent analyst reports. Rodman & Renshaw started coverage on shares of INmune Bio in a report on Tuesday, January 28th. They set a "buy" rating and a $23.00 price target on the stock. Scotiabank increased their target price on shares of INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, February 11th. RODMAN&RENSHAW upgraded INmune Bio to a "strong-buy" rating in a research note on Tuesday, January 28th. Finally, Maxim Group increased their price target on INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, INmune Bio currently has an average rating of "Buy" and a consensus price target of $22.80.

INmune Bio Price Performance

INMB stock traded down $0.43 during trading on Tuesday, hitting $7.12. The stock had a trading volume of 306,034 shares, compared to its average volume of 252,975. INmune Bio, Inc. has a twelve month low of $4.32 and a twelve month high of $11.47. The company's 50-day moving average price is $7.74 and its two-hundred day moving average price is $6.83. The stock has a market capitalization of $163.65 million, a P/E ratio of -3.27 and a beta of 1.63.

INmune Bio (NASDAQ:INMB - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.14. As a group, sell-side analysts expect that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.